A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

NCT04236141 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision, no safety concerns

Conditions

Diffuse, Large B-Cell, Lymphoma

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Bendamustine
DRUG: Rituximab
DRUG: Placebo

Sponsor

Hoffmann-La Roche